MedTrace Logo

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LP-98 Injection in Healthy Subjects

NCT05933824 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2026-05-15

No results posted yet for this study

Summary

A randomized, placebo-controlled, single-administration, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of LP-98 injection in healthy subjects in a first-in-human clinical study

Conditions

  • HIV (Human Immunodeficiency Virus)

Interventions

DRUG

LP-98 injection

Part A is administration is by subcutaneous LP98/placebo,Part B is administration is by intravenous drip LP98/placebo

Sponsors & Collaborators

  • Institute of Pathogen Biology, Beijing, China

    collaborator OTHER

  • Shanxi Kangbao Biological Product Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Shuang Li, Master · Henan Provincial Hospital for Infectious Diseases (Zhengzhou Sixth People's Hospital)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-07-13
Primary Completion
2024-04-12
Completion
2024-04-12

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05933824 on ClinicalTrials.gov